BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, August 12, 2013
least 20 biotechs and pharmas reported earnings last week. Regeneron
Pharmaceuticals Inc. (NASDAQ:REGN) dropped 8%, losing more than $2 billion
in market value, after posting EPS and revenues that disappointed Wall Street
analysts. The biotech did raise its 2013 revenue guidance for macular
degeneration drug Eylea aflibercept to $1.3-$1.35 billion from $1.25-$1.33
billion, and announced plans to submit an sBLA to FDA for Eylea to treat
diabetic macular edema (DME) this year, about one year ahead of the company's
previously announced timeframe.
Corp. (NASDAQ:DNDN), which markets prostate cancer therapy Provenge
sipuleucel-T, fell 26% after posting EPS and revenues that missed analyst
consensus estimates. The biotech said it does not expect to see enough of a
sales increase in 2H13 to meet its goal of growing Provenge year-over-year.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]